New Reference: Encorafenib and Binimetinib in bRAF V600E Mutated NSCLC

Phase II, single-arm study (PHAROS)

Treatment-naïve and previously treated with BRAFV600E-mutant metastatic NSCLC

Encorafenib +Bininmetinib q28 (n=98)

ORR: 75.0% [62%-85%] in treatment naïve and 46% [30%-63%) in previously treated group

mDOR: NR and 16.7 mos

mPFS: NR and 9.3 mos [6.2-NR]

Grade3 Aes: ALT increased (5%), AST increased (7%), diarrhea (4%), anemia (3%).

Reviewed by Elvin Chalabiyev, MD on Jun 24, 2023